Révolutionner les soins,
transformer des vies.

Are you interested in exploring a health condition with our digital odor perception platform? Our team will work side-by-side with you to bring a clinical solution to life and push the boundaries of what digital odor perception can do in healthcare. Whether you're in the ideation stage or ready for clinical trials, the doors of Noze labs are open.
Dévouées à l’amélioration des résultats pour les patients, nos études cliniques utilisent le capteur d’haleine diagnostique le plus avancé au monde pour développer des outils de détection précoce des maladies. Plusieurs études sont en cours en partenariat avec des partenaires cliniques de renommée mondiale.
Dedicated to the fight for
better patient
outcomes,
our clinical studies utilize the
world's
most advanced diagnostic
breathalyzer
to develop early disease
detection tools. We have studies underway
with multiple
renowned clinical partners.
Leveraging our digital odor perception platform, we’ve successfully built the world’s first fully-integrated breathalyzer for early screening and diagnostics. Our ongoing concurrent phase-1 studies are conducted in collaboration with highly respected clinical sites.

Domaines diagnostiques principaux :

Plus de 50 millions de personnes dans le monde vivent avec l’épilepsie. Les crises peuvent entraîner des blessures, des chutes, voire pire. Nous explorons des technologies de prédiction pour permettre aux patients d’agir de manière préventive.

En savoir plus

More than 4 in 10 adults have high cholesterol and don’t even know it, significantly raising their risk of irreversible heart disease. We’re running a study to non-invasively detect the presence of high cholesterol in patients and to determine the effects of statin treatment on these patients. We’re nearing the end of this study with promising empirical evidence on the horizon.

Learn more

L’essoufflement chronique peut signaler des problèmes respiratoires ou cardiovasculaires, compliquant le diagnostic et retardant le traitement. Nous développons une solution pour identifier rapidement l’origine de la dyspnée.

En savoir plus

Les adultes atteints de diabète ont deux fois plus de risques de mourir de maladies cardiaques ou d’AVC, soulignant l’importance du dépistage précoce et d’une bonne gestion. Nous développons une solution sans consommable pour détecter et surveiller le diabète.

Learn more

Plus d’un million de personnes meurent chaque année de la tuberculose, faute d’accès au dépistage et au traitement. Nous développons un outil de dépistage en temps réel, à haut rendement, en partenariat avec la Fondation Bill & Melinda Gates.

En savoir plus

Les mammographies coûtent plus de 4 milliards de dollars par an aux États-Unis. Nous développons un outil de dépistage précoce pour réduire les coûts, l’inconfort et l’exposition aux radiations, tout en contournant les difficultés liées aux tissus mammaires denses.

En savoir plus

Malgré les risques liés aux diagnostics tardifs, seulement 5 % des personnes éligibles ont été dépistées aux États-Unis en 2022. Nous développons un outil pour favoriser le dépistage précoce et améliorer les taux de survie.

En savoir plus

More than 4 in 10 adults have high cholesterol and don’t even know it, significantly raising their risk of irreversible heart disease. We’re running a study to non-invasively detect the presence of high cholesterol in patients and to determine the effects of statin treatment on these patients. We’re nearing the end of this study with promising empirical evidence on the horizon.

Learn more

Shortness of breath - or dyspnea - can be a symptom of respiratory disease, cardiovascular disease, or both. This makes identifying an ideal treatment course crucial for patients presenting to our overloaded emergency rooms with this common symptom. We’re running a study to evaluate our breathalyzer’s ability to distinguish between a cardiovascular and pulmonary cause of dyspnea, an opportunity to triage for appropriate and proactive treatment. Study launch expected in xxxx

Learn more

Despite being entirely preventable and curable, Tuberculosis claims over a million lives annually because of limited access to timely testing and treatment in developing countries. In partnership with the Bill and Melinda Gates Foundation, we’re spearheading an initiative to use our breathalyzer for Tuberculosis screening in these regions and curb the spread of this deadly disease. Study launch planned for June 2024.

Learn more

Adults with diabetes are twice as likely to die from heart disease or stroke, highlighting the importance of early detection for effective disease management. Our study focuses on non-invasive breath analysis for the early detection of Type II diabetes, eliminating the necessity for more invasive testing methods. Currently securing ethics approval, we anticipate launching this study in February 2024.

Learn more

With the Centre Hospitalier University de Montreal (CHUM) we are testing skin-based screening of diagnostics using our wearable technology.

Learn more

The average cost of a mammogram is $250 USD. We’re running a study to detect the presence of breast cancer early, when the disease is at its most treatable, ushering a new era where early detection becomes synonymous with survival. We’re currently recruiting patients and collecting breath samples. Stay tuned for more.

Learn more

Lung cancer symptoms often manifest only when it's too late. Despite this, only 5% of eligible patients in the United States were screened for lung cancer in 2022. Early detection of lung cancer can significantly improve survival rates and decrease treatment costs, highlighting the urgency to revolutionize screening practices for improved outcomes in the battle against lung cancer.Stay tuned for more on our work with lung cancer. We’re just getting started.

Learn more

Stay tuned, we’re just getting started

Learn more

Stay tuned, we’re just getting started

Learn more

Stay tuned, we’re just getting started

Learn more

Our Clinical Studies Pipeline

Diagnostic area
Condition
Pre-clinical
Phase 1: Discovery
Phase 2: Origination
Phase 3: Pivotal
Authorized use
anticipated start dates
Respiratory
Oncology
Metabolic
Oncology
Cardiovascular
Epilepsy
Tuberculosis
Breast Cancer
Diabetes
Lung Cancer
Dyspnea
Neurological
In progress
In progress
In progress
Q3 24
In recruitment
In recruitment
Q3 24
Q3 24
Q2 24
Q1 25
Q4 24
Q4 24
Q1 25
Q1 25
Q4 24
Q1 26
Q3 25
Q4 25
Q3 25
Q3 25
Q2 25
Q3 27
Q1 27
Q1 27
Q3 27
Q3 27
Q2 27
Diagnostic area
Respiratory
Condition
Tuberculosis
Pre-clinical
Phase 1: Discovery
Q3 24
Phase 2: Origination
Q1 25
Phase 3: Pivotal
Q1 26
Authorized use
Q3 27
Diagnostic area
Oncology
Condition
Breast Cancer
Pre-clinical
Phase 1: Discovery
In recruitment
Phase 2: Origination
Q4 24
Phase 3: Pivotal
Q3 25
Authorized use
Q1 27
Diagnostic area
Metabolic
Condition
Diabetes
Pre-clinical
Phase 1: Discovery
In recruitment
Phase 2: Origination
Q4 24
Phase 3: Pivotal
Q4 25
Authorized use
Q1 27
Diagnostic area
Oncology
Condition
Lung Cancer
Pre-clinical
In progress
Phase 1: Discovery
Q3 24
Phase 2: Origination
Q1 25
Phase 3: Pivotal
Q3 25
Authorized use
Q3 27
Diagnostic area
Cardiovascular
Condition
Dyspnea
Pre-clinical
In progress
Phase 1: Discovery
Q3 24
Phase 2: Origination
Q1 25
Phase 3: Pivotal
Q3 25
Authorized use
Q3 27
Diagnostic area
Epilepsy
Condition
Neurological
Pre-clinical
in progress
Phase 1: Discovery
Q2 24
Phase 2: Origination
Q4 24
Phase 3: Pivotal
Q2 25
Authorized use
Q2 27
Rencontrez nos partenaires cliniques

Nos partenaires jouent un rôle essentiel dans la construction des soins de santé de demain. Leur engagement sans faille nous rapproche toujours un peu plus de notre vision.

Let’s talk

Vous souhaitez en savoir plus sur l’une de nos études cliniques ? Vous avez une ou dix questions ? Laissez-nous vos coordonnées et un de nos experts vous contactera.

Thanks for contacting us!
One of Noze's team members will reach out to you shortly.
Oops! Something went wrong while submitting the form.